Invesco Ltd. Editas Medicine, Inc. Transaction History

Invesco Ltd.

$460 Billion
Q2 2024

A detailed history of Invesco Ltd. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 87,453 shares of EDIT stock, worth $304,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares

87,453

Previous 86,961 0.57%

Holding current value

$304,336

Previous $645,000 36.74%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $2,297 - $3,581	492 Added 0.57%	87,453 $408,000
Q1 2024 May 14, 2024	SELL	$7.03 - $11.07 $24,548 - $38,656	-3,492 Reduced 3.86%	86,961 $645,000
Q4 2023 Feb 12, 2024	BUY	$6.25 - $11.11 $48,662 - $86,502	7,786 Added 9.42%	90,453 $916,000
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $17,168 - $23,098	2,481 Added 3.09%	82,667 $644,000
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $8,649 - $15,599	1,360 Added 1.73%	80,186 $659,000
Q1 2023 May 12, 2023	BUY	$7.03 - $11.53 $162,048 - $265,778	23,051 Added 41.33%	78,826 $571,000
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $1,888 - $2,998	-227 Reduced 0.41%	55,775 $494,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $21,766 - $34,761	-1,790 Reduced 3.1%	56,002 $685,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $15,894 - $33,967	1,591 Added 2.83%	57,792 $683,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $291,624 - $572,272	20,712 Added 58.36%	56,201 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $76,118 - $116,314	-2,867 Reduced 7.47%	35,489 $942,000
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $189,988 - $352,883	4,838 Added 14.43%	38,356 $1.58 Million
Q2 2021 Aug 17, 2021	BUY	$31.29 - $56.64 $364,246 - $659,346	11,641 Added 53.21%	33,518 $1.9 Million
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $711,603 - $1.62 Million	-17,920 Reduced 45.03%	21,877 $919,000
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $735,112 - $2.29 Million	27,156 Added 214.82%	39,797 $2.79 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $3,956 - $5,239	-141 Reduced 1.1%	12,641 $355,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $19,924 - $36,984	-1,077 Reduced 7.77%	12,782 $378,000
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $48,389 - $106,600	3,252 Added 30.66%	13,859 $274,000
Q4 2019 Feb 14, 2020	SELL	$19.49 - $32.63 $13,662 - $22,873	-701 Reduced 6.2%	10,607 $314,000
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $9,985 - $11,903	-444 Reduced 3.78%	11,308 $257,000
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $8,478 - $11,492	-414 Reduced 3.4%	11,752 $291,000
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $483,651 - $657,397	-24,892 Reduced 67.17%	12,166 $297,000
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $674,085 - $1.18 Million	37,058 New	37,058 $843,000

Others Institutions Holding EDIT

# of Institutions

252

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $239M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account